These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38293701)

  • 1. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer.
    Zhang C; Zhou F; Zou J; Fang Y; Liu Y; Li L; Hou J; Wang G; Wang H; Lai X; Xie L; Jiang J; Yang C; Huang Y; Chen Y; Zhang H; Li Y
    Front Oncol; 2023; 13():1322078. PubMed ID: 38293701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.
    Glaviano A; Wander SA; Baird RD; Yap KC; Lam HY; Toi M; Carbone D; Geoerger B; Serra V; Jones RH; Ngeow J; Toska E; Stebbing J; Crasta K; Finn RS; Diana P; Vuina K; de Bruin RAM; Surana U; Bardia A; Kumar AP
    Drug Resist Updat; 2024 Sep; 76():101103. PubMed ID: 38943828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy.
    Akdag G; Dogan A; Yildirim S; Kinikoglu O; Mokresh ME; Alomari O; Turkoglu E; Isik D; Sürmeli H; Basoglu T; Sever ON; Odabas H; Yildirim ME; Turan N
    Cureus; 2024 Jun; 16(6):e63362. PubMed ID: 39070363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
    O'Sullivan CC; Clarke R; Goetz MP; Robertson J
    JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report:
    Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
    Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
    Sammons S; Raskina K; Danziger N; Alder L; Schrock AB; Venstrom JM; Knutson KL; Thompson EA; McGregor K; Sokol E; Chumsri S
    JCO Precis Oncol; 2022 Oct; 6():e2200149. PubMed ID: 36315915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
    Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
    Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.
    Torres-Guzmán R; Ganado MP; Mur C; Marugan C; Baquero C; Yang Y; Zeng Y; Bian H; Du J; de Dios A; Puig O; Lallena MJ
    Oncotarget; 2022; 13():864-875. PubMed ID: 35813283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
    Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.
    Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC
    Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
    Gul A; Leyland-Jones B; Dey N; De P
    Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.
    O'Sullivan CC
    Int J Cancer Clin Res; 2015; 2(4):. PubMed ID: 26726315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CDK4/6 inhibitors in early breast cancer.
    Gil-Gil M; Alba E; Gavilá J; de la Haba-Rodríguez J; Ciruelos E; Tolosa P; Candini D; Llombart-Cussac A
    Breast; 2021 Aug; 58():160-169. PubMed ID: 34087775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.
    Edessa D; Sisay M
    Breast Cancer (Dove Med Press); 2017; 9():567-579. PubMed ID: 29263697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer.
    Sobhani N; Fassl A; Mondani G; Generali D; Otto T
    Cells; 2021 Feb; 10(2):. PubMed ID: 33535617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.